Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 163-165

  Lewis, Roshan ^a   Hogan, Holly ^a   Howell, Allan ^a   Safdar, Amar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CLARITHROMYCIN; CLOFARABINE; CYCLOPHOSPHAMIDE; DOXYCYCLINE; GAMMA1B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; MICAFUNGIN; POSACONAZOLE; RECOMBINANT GAMMA INTERFERON; VORICONAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEBRIDEMENT; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FUNGICIDAL ACTIVITY; FUSARIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LYMPHATIC LEUKEMIA; MYCOSIS; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN NODULE;

ADULT; BIOLOGICAL AVAILABILITY; FUSARIUM; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA, RECOMBINANT; LEUKEMIA; MALE; MYCOSES; NEUTROPENIA; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 38549165159     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701724819     Document Type: Article

References (16)

1. Safdar, A. (2006) Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone marrow Transplant, 38, pp. 327-337.
2. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E. and Oestmann, J. W. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, pp. 408-415.
3. Trifilio, S., Pennick, G. and Pi, J. (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer, 109, pp. 1532-1535.
4. Trifilio, S. M., Bennett, C. L. and Yarnold, P. R. (2007) Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant, 39, pp. 425-429.
5. Raad, I. I., Hachem, R. Y. and Herbrecht, R. (2006) Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis, 42, pp. 1398-1403.
6. Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J. and Laughlin, M. (2005) Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet, 44, pp. 211-220.
7. Safdar, A., Rodriguez, G. H. and Lichtiger, B. (2006) Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer, 106, pp. 2664-2671.
8. Heyn, K., Tredup, A., Salvenmoser, S. and Muller, F. M. (2005) Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother, 49, pp. 5157-5159.
9. Courtney, R., Wexler, D., Radwanski, E., Lim, J. and Laughlin, M. (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol, 57, pp. 218-222.
10. Courtney, R., Sansone, A., Calzetta, A., Marinho, M. and Laughlin, M. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole [abstract]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL
11. Ullmann, A. J., Cornely, O. A. and Bruchardt, A. (2006) Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrobial Agents Chemother, 50, pp. 658-666.
12. Walsh, T., Patterson, T. and Langston, A. (2007) Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: An externally controlled blinded trial. Clin Infect Dis, 44, pp. 2-12.
13. (2006) Noxafil, Schering Corporation, Kenilworth, NJ
14. Arkan, S., Lozano-Chiu, M., Paetznick, V. and Rex, J. H. (2002) In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrobial Agents Chemother, 46, pp. 245-247.
15. Gil-Lamaignene, C., Simitsopoulou, M., Roilides, E., Maloukou, A., Winn, R. M. and Walsh, T. J. (2005) Interferon-gamma and granulocyte-macrophge colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis, 191, pp. 1180-1187.
16. Roilides, E., Holmes, A., Blake, C., Venzon, D., Pizzo, P. A. and Walsh, T. J. (1994) Antifungal activity of elutriated human monocytes against Aspergillus fumigatus haphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis, 170, pp. 894-899.